Spero Therapeutics

Spero has a pipeline of novel treatments for multi-drug resistant (MDR) bacterial infections.

Two programs are in clinical phase I

�鶹�� BioCapital

Invested

2015

IPO in 2017 – SPRO (Nasdaq)

Location

Boston, Massachusetts, USA

�鶹��